Provided by Tiger Trade Technology Pte. Ltd.

Anti-Pandemic Concept

1,834.82
+26.851.49%
Number of Gainers:8
Number of Losers:11
Number of Flat:- -
PE:- -
High:1,846.22
Open:1,807.96
Low:1,807.96
Close:1,807.97
Volume:94.07M
Turnover:7.41B
Market Cap:1.49T
Float Cap:1.46T

Loading ...

Pfizer Says Phase 3 Trials Show Litfulo Improves Repigmentation in Nonsegmental Vitiligo Patients at Week 52

Reuters
·
Oct 02

Pfizer - to Submit Litfulo Phase 3 Data to FDA and Ema

THOMSON REUTERS
·
Oct 02

Pfizer - Litfulo Safety Profile in Nsv Consistent with Alopecia Areata; no New Safety Signals

THOMSON REUTERS
·
Oct 02

Pfizer’s Litfulo Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo~

THOMSON REUTERS
·
Oct 02

Cboe data shows mixed options sentiment in Moderna with shares down 1.81%

TIPRANKS
·
Oct 02

Moderna Shares Reverse Course, Last Down 1.3%

THOMSON REUTERS
·
Oct 02

Nvidia, Tesla, Seagate, on Semi, Strategy, HPE, and More Stocks That Explain Today's Market

Dow Jones
·
Oct 02

Update: US Equity Futures Higher Pre-Bell as Traders Monitor Oil Prices, Assess September Jobs Report

MT Newswires Live
·
Oct 02

U.S. Stocks on the MOVE-Moderna, Nike, Synaptics

Reuters
·
Oct 02

Warburg Research Keeps Their Buy Rating on Deutsche Boerse (0H3T)

TIPRANKS
·
Oct 02

US Stocks-Wall St Futures Rise Ahead of Jobs Report as Bond Market Steadies, Oil Slips

Reuters
·
Oct 02

On Semi, Synaptics, Nike, Strategy, Moderna, and More Stocks That Explain Today's Market

Dow Jones
·
Oct 02

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Tilray (TLRY)

TIPRANKS
·
Oct 02

Berenberg Bank Sticks to Its Buy Rating for Bechtle Aktiengesellschaft (0DPM)

TIPRANKS
·
Oct 02

Warner Bros. Stock is About to Leave the Nasdaq. Here's What's Replacing It.

Dow Jones
·
Oct 02

Jefferies Adjusts Price Target on Pfizer to $35 From $34, Keeps Buy Rating

MT Newswires Live
·
Oct 02

J&J - Icotyde-Treated Patients Show 70% Clear or Almost Clear Skin at Week 112

THOMSON REUTERS
·
Oct 02

Johnson & Johnson Announces New Icotyde® (Icotrokinra) Data in Difficult-to-Treat Plaque Psoriasis with Proven Durability Through 2-Years, Affirming Its Use as a Powerful First Line Systemic Therapy~

THOMSON REUTERS
·
Oct 02

J&J - Safety Findings Through Week 112 Consistent with Icotyde Profile, no New Safety Signals

THOMSON REUTERS
·
Oct 02

Summit Therapeutics enters trial collaboration with AstraZeneca, Daiichi Sankyo

TIPRANKS
·
Oct 02